Biomedical Engineering Reference
In-Depth Information
9. Loppow D, Schleiss MB, Kanniess F, Taube C, Jorres RA, Magnussen H. In
patients with chronic bronchitis a four week trial with inhaled steroids does
not attenuate airway inflammation. Respir Med 2001; 95:115-121.
10. Culpitt SV, Rogers DF, Shah P, de Matos C, Russell RE, Donnelly LE, et al.
Impaired inhibition by dexamethasone of cytokine release by alveolar macro-
phages from patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2003; 167:24-31.
11. Wright JL, Churg A. Animal models of cigarette smoke-induced COPD.
Chest 2002; 122:301S-306S.
12. Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, Nides MA, et al.
Smoking cessation in patients with chronic obstructive pulmonary disease: a
double-blind, placebo controlled,
randomised trial. Lancet 2001; 357:
1571-1575.
13. George TP, O'Malley SS. Current pharmacological treatments for nicotine
dependence. Trends Pharmacol Sci 2004; 25:42-48.
14. Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry
2003; 8:255-256.
15. Kantak KM. Vaccines against drugs of abuse: a viable treatment option?
Drugs 2003; 63:341-352.
16. GOLD. Global Initiative for Chronic Obstructive Lung Disease (GOLD): glo-
bal strategy for the diagnosis, management of chronic obstructive pulmonary
disease. NHLBI
=
WHO Workshop Report
2003; www.goldcopd.-
com
=
workshop
=
index.html.
17. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholiner-
gic bronchodilator for the treatment of COPD. Drugs Today 2002; 38:
585-600.
18. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L,
et al. Improved health outcomes in patients with COPD during 1 yr's treat-
ment with tiotropium. Eur Respir J 2002; 19:209-216..
19. Tennant RC, Erin EM, Barnes PJ, Hansel TT. Long-acting b2-adrenoceptor
agonists or tiotropium bromide for patients with COPD: is combination ther-
apy justified? Curr Opin Pharmacol 2003; 3:270-276.
20. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in
chronic obstructive pulmonary disease: a systematic review of randomized
placebo-controlled trials. Am J Med 2002; 113:59-65.
21. Bames PJ, Ito K, Adcock IM. A mechanism of corticosteroid resistance in
COPD: inactivation of histone deacetylase. Lancet 2004; 363:731-733.
22. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, et al. A mole-
cular mechanism of action of theophylline: induction of histone deacetylase
activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA
2002; 99:8921-8926..
23. Barnes PJ. Theophylline: new perspectives on an old drug. Am J Respir Crit
Care Med 2003; 167:813-818.
24. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S,
et al. Efficacy and safety of budesonide
=
formoterol in the management
of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
